Loncastuximab tesirine

From WikiMD.org
Jump to navigation Jump to search

Loncastuximab Tesirine

Loncastuximab Tesirine (pronunciation: lon-kas-tux-i-mab te-si-rine) is a monoclonal antibody-drug conjugate used for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Etymology

The name "Loncastuximab Tesirine" is derived from the components of the drug. "Lonca" refers to the monoclonal antibody that targets the CD19 antigen on B cells. "Tesirine" refers to the pyrrolobenzodiazepine (PBD) dimer cytotoxic agent that is attached to the antibody.

Usage

Loncastuximab Tesirine is used for the treatment of adult patients with relapsed or refractory DLBCL, including DLBCL arising from low grade lymphoma, and who have received at least two prior therapies.

Mechanism of Action

Loncastuximab Tesirine works by binding to the CD19 antigen on the surface of B cells, which is then internalized into the cell where the cytotoxic agent is released. This causes DNA damage and cell death.

Related Terms

Side Effects

Common side effects of Loncastuximab Tesirine include fatigue, nausea, diarrhea, cough, and fever. Serious side effects can include low blood cell counts, infection, and liver problems.

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski